A Phase 2 interventional study of AT-1501 in Type 1 Diabetes Mellitus, sponsored by Anelixis Therapeutics, LLC. Withdrawn at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-08-10.
Sponsored by Anelixis Therapeutics, LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 318 studies in Diabetes Mellitus, Type 1 with a site in Canada — 48 open to participants now, 61 under way, 15 of them phase 3. Diabetes Mellitus, Type 1 · Canada.
Among the 318 studies in Diabetes Mellitus, Type 1 with a site in Canada, this one is the 267th largest by enrollment of the 274 interventional ones that give a count, is one of 18 that started in 2021, is one of 59 in phase 2, and was the 224th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →48 of the 318 studies in Diabetes Mellitus, Type 1 with a site in Canada are open now. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
Kriya Therapeutics, Inc. · Sites in Canada, New Zealand
Ages 18–65
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada, Switzerland
Ages 18+
ClinSurge Research · Sites in Canada
Ages 18+
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in Canada, United States
Ages 8–45
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
318 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 79 · Phase 3 70 · Phase 4 12
First in 1983; this study’s year is marked. 18 started in 2021.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 45 across the 274 interventional studies, 205 across the 44 observational. Of the 230 that completed or were terminated, 73 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 318 have an industry lead sponsor. The 10 most frequent:
Anelixis Therapeutics, LLC is the lead sponsor of 2 studies on the registry; none are open to participants now.
Anelixis Therapeutics, LLC has 1 study filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
25 of the studies in Diabetes Mellitus, Type 1 with a site in Canada that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06894784Phase 3McGill University Health Centre/Research Institute of the McGill University Health CentreA Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes | 2027-01 |
| NCT06387199Phase 3McGill University Health Centre/Research Institute of the McGill University Health CentreAlleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide | 2027-01 |
| NCT07076199Phase 3Novo Nordisk A/SA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | 2027-01-25 |
| NCT04598893Provention Bio, a Sanofi CompanyRecent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension) | 2026-11 |
Add all 25 to your calendar (.ics) → With an account.
Among the 318 studies in Diabetes Mellitus, Type 1 with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.
This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant. This study will also provide valuable data with respect to its potential additional uses in autoimmunity and solid organ transplant. This is a single arm open-label study and up to 6 participants will be recruited at a single center in Canada.
The objectives include:
The duration of treatment may vary from participant to participant and could be up to 20 months. Participants may receive up to 2 islet cell transplants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AT-1501
AT-1501 IV infusion
Safety- Adverse Events (AE) and Adverse Events of Special Interest (AEoSI)
Incidence of adverse events
Time frame: Accessed from date of transplant through 1 year post transplant for approximately 2 years
Efficacy- Insulin independence
Change in the proportion of participants that become insulin independent at Days 75 and 365 post-first, and final transplant
Time frame: Days 75 , Day 365 post-first transplant, and final transplant and 1 year after discontinuation of AT-1501
Efficacy- Graft failure
Proportion of participants with graft failure
Time frame: Day 365
Efficacy- Durability of insulin independence- long term
Change in the proportion of participants that become insulin independent at year 2 and year 3
Time frame: 2 and 3 years after discontinuation of AT- 1501
Efficacy- HbA1c
* Proportion of participants with HbA1c \<7.0% (53 mmol/mol) and free of serious hypoglycemic events (SHEs) * Proportion of participants with HbA1c ≤6.5% (48 mmol/mol) and free from SHEs
Time frame: Day 365 and free of serious hypoglycemic events from Day 28 to 365 post-first transplant
Exploratory- Hypoglycemia unawareness (using the method of Clarke)
Proportion of participants with hypoglycemia unawareness
Time frame: Day 75, 365, and 1, 2 and 3 years after discontinuation of AT-1501
Exploratory- Glycemic lability (using CGMS)
Change in glycemic lability using CGMS- Continuous Glucose Monitoring System
Time frame: Day 75, 365, and 1, 2 and 3 years after discontinuation of AT-1501
Exploratory- Glycemic variability (using CGMS)
Change in glycemic variability using CGMS- Continuous Glucose Monitoring System
Time frame: Day 75, 365, and 1, 2 and 3 years after discontinuation of AT-1501
Exploratory- Albumin excretion ratio (AER)
Change in albumin excretion ratio (AER)
Time frame: Day 365 post-first, and final transplant
Exploratory- eGRF
Change in eGRF
Time frame: Day 365 post-first, and final transplant
Exploratory- Macroalbuminemia
Change in percent new macroalbuminemia
Time frame: Day 365 post-first, and final transplant
Exploratory- biomarkers of tissue damage and inflammation
Biomarkers
Time frame: Day -2, 3, 14, 28, 75, 175, 364
Exploratory -Pharmacokinetic Parameters-AUC
Pharmacokinetics (PK) of AT-1501
Time frame: T=0 (pre infusion), 1 (end of infusion), 2, 4, 8, 12, 24 and 48 hrs.
Exploratory- Pharmacokinetic Parameters-Cmax
Pharmacokinetics (PK) of AT-1501
Time frame: T=0 (pre infusion), 1 (end of infusion), 2, 4, 8, 12, 24 and 48 hrs.
Exploratory- Pharmacokinetic Parameters-CL
Pharmacokinetics (PK) of AT-1501
Time frame: T=0 (pre infusion), 1 (end of infusion), 2, 4, 8, 12, 24 and 48 hrs.
Exploratory- Pharmacokinetic Parameters- Vdss
Pharmacokinetics (PK) of AT-1501
Time frame: T=0 (pre infusion), 1 (end of infusion), 2, 4, 8, 12, 24 and 48 hrs.
Exploratory- Pharmacokinetic Parameters- (t1/2)
Pharmacokinetics (PK) of AT-1501
Time frame: T=0 (pre infusion), 1 (end of infusion), 2, 4, 8, 12, 24 and 48 hrs.
Started Feb 2021 (actual). Primary completion is estimated for Jun 2024, 40 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tegoprubart
Anelixis Therapeutics, LLC